I am grateful to be able to bring the debate to the chamber today, and I thank members from across the Parliament for all their support on what is not only an important public health issue globally but, increasingly, a potential threat to domestic health security.
I pay tribute to the Edinburgh group of Results UK, which campaigns on international development issues, including tuberculosis. I have been working with the group since my election to Parliament in 2016, and I am pleased to welcome some of its members to the public gallery today. I have also sponsored a stand just outside the chamber, and I know that a number of members have already spoken to and engaged with the group. If they have not done so already, there may be a chance after the debate for them to speak to the group and find out more information.
I also take the opportunity to note the contribution made by two leading professionals in Scotland. Dr Helen Stagg of the centre for population health sciences at the University of Edinburgh was, until recently, chair of the UKAPTB. For those who do not know what that is, it stands for UK Academics and Professionals to End TB. Susan Duthie, who is the lead TB specialist nurse at NHS Grampian, also led on drawing up recommendations on the management of Afghan national TB screening in Scotland.
I also put on record our thanks for all the vital work that is carried out by clinical staff, scientists and civil society organisations, in Scotland and globally, to deliver on the sustainable development goal, which we all signed up to, of ending TB by 2030.
Tuberculosis is an incredibly infectious disease that is spread through coughing. It has killed more people than any other single infectious agent in history, including SARS-CoV-2. TB is curable, but people need support to get through the many months of treatment that are required.
As noted in the motion, around 1.5 million people die from TB every year and many millions more are diagnosed with the disease. That is a shocking statistic and something that we all need to reflect on. Presiding Officer, if you were a teenager before 2005—I am not sure whether you were—you may bear a small, circular scar on your bicep. That is by-product of immunisation against TB and a reminder of the prevalence of the disease in this country at one time.
However, the Covid-19 pandemic and its widespread effects on diagnosis and treatment have brought the disease of TB back to the forefront of the policy debate, especially in the context of public health in developing countries. Because of the similarities between TB and Covid, much of the precautionary equipment and many of the treatment centres and services that are usually the first line of defence for the former were refocused on the latter. The World Health Organization has suggested that the pandemic has set back efforts to end TB globally by more than a decade.
Researchers at the University of Dundee, who received a £3.8 million grant from the Bill & Melinda Gates Foundation to develop treatments, have warned that the impact of the pandemic could lead to a rise in tuberculosis infections around the world, as some patients will have gone undiagnosed amid the pandemic. Indeed, as with many services across our health landscape, we believe that diagnoses of TB dropped by around 20 per cent in 2020, as access to treatment became increasingly difficult.
Some projections suggest that progress against TB has also been significantly set back. Dr Laura Cleghorn of the University of Dundee said that there is a “pressing need” to develop new treatments for the illness, which some people wrongly think of as a “disease of yesteryear” . I agree. As I said earlier, it is a concern that, across the world, diagnoses of TB dropped by a similar level, with 16 countries accounting for 93 per cent of that drop. That suggests that countries that already have a higher burden of disease have fared far worse.
Of course, other issues have led to that protracted problem. For example, fewer people have been tested for TB and the number attending for tests has reduced. That might be due to people’s fear of contracting Covid-19 in hospital or because people with Covid-19 were not able to go to hospital. As we emerge from the pandemic, we urgently need to tackle that problem. Otherwise, we risk stepping backwards in the fight against deaths from TB.
That will, of course, require a sincere, co-ordinated and multilateral effort, but if the pandemic has demonstrated anything it is that immense benefit can sometimes be gained from proper and targeted investment in global public health. In recent years, concerted action has been taken to tackle TB and we need to see that work being recovered.
In 2018, for example, we saw the first high-level global meeting on TB. It produced a declaration of political will that can shape our approach going forward. Notably, it identified work to close the research and development funding gap. To date, that has been estimated to be more than $1.1 billion. I welcome the £20 million of UK Government research and development funding. A good portion of that has already been targeted towards such global health innovations.
There are still many concerns around research and development, and I hope that we can address those globally.
The first and most obvious concern is about treatment methods. Innovation will allow us to simplify treatment regimes, allowing them to be more easily deployed in all corners of the world, in contrast to what are currently lengthy and complex treatments for many patients that can often take more than three months.
Similarly, we need to see progress on diagnosis of TB. We need to be able to do it in a speedy, efficient and simple way. To circle back to my earlier points, Covid-19 has acted as a catalyst to the diagnosis question, and I hope that we will see investment around early diagnosis of TB, as we have seen around Covid.
Finally, and perhaps most importantly, we need to fund the research that will look at drug resistance. We are all acutely aware of a really worrying trend—a rise in drug-resistant or multidrug-resistant TB. More than 160,000 cases were recorded people last year alone, which is deeply concerning for global public health.
We know that Scotland is also behind in funding for latent TB screening in communities at risk and vulnerable to TB. I hope that the minister who closes the debate can outline the public health initiatives that are being developed to address those concerns around latent TB screening.
To conclude, I am incredibly grateful to members for allowing me to introduce the debate today, and for the opportunity to discuss these issues of public health policy around the world and of domestic health security.
Above all, I hope that today can present an opportunity for Parliament to re-affirm our collective mission and that of clinical staff, scientists and civil society organisations in Scotland and globally to meet the sustainable development goal of ending TB by 2030.